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Abstract: INTRODUCTION The amount of residual tumor burden after neoadjuvant chemotherapy
is an important prognosticator, but for non-small cell lung carcinoma (NSCLC), no official regression
scoring system is yet established. Computationally derived histological regression scores could provide
unbiased and quantitative readouts to complement the clinical assessment of treatment response. METH-
ODS Histopathologic tumor regression was microscopically assessed on whole cases in a neoadjuvant
chemotherapy-treated cohort (NAC, n = 55 patients) of lung squamous cell carcinomas (LSCC). For
each patient, the slide showing the least pathologic regression was selected for subsequent computational
analysis and histological features were quantified: percentage of vital tumor cells (cTu.Percentage), total
surface covered by vital tumor cells (cTu.Area), area of the largest vital tumor fragment (cTu.Size.max),
and total number of vital tumor fragments (cTu.Fragments). A chemo-naïve LSCC cohort (CN, n =
104) was used for reference. For 23 of the 55 patients [18F]-Fluorodeoxyglucose (FDG) PET/CT mea-
surements of maximum standard uptake value (SUVmax), background subtracted lesion activity (BSL)
and background subtracted volume (BSV) were correlated with pathologic regression. Survival analysis
was carried out using Cox regression and receiver operating characteristic (ROC) curve analysis using
a 3-years cutoff. RESULTS All computational regression parameters significantly correlated with rel-
ative changes of BSV FDG PET/CT values after neoadjuvant chemotherapy. ROC curve analysis of
histological parameters of NAC patients showed that cTu.Percentage was the most accurate prognos-
ticator of overall survival (ROC curve AUC = 0.77, p-value = 0.001, Cox regression HR = 3.6, p =
0.001, variable cutoff < = 30 %). CONCLUSIONS This study demonstrates the prognostic relevance of
computer-derived histopathologic scores. Additionally, the analysis carried out on slides displaying the
least pathologic regression correlated with overall pathologic response and PET/CT values. This might
improve the objective histopathologic assessment of tumor response in neoadjuvant setting.
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A B S T R A C T
Introduction: The amount of residual tumor burden after neoadjuvant chemotherapy is an important prog-
nosticator, but for non-small cell lung carcinoma (NSCLC), no official regression scoring system is yet estab-
lished. Computationally derived histological regression scores could provide unbiased and quantitative readouts
to complement the clinical assessment of treatment response.
Methods: Histopathologic tumor regression was microscopically assessed on whole cases in a neoadjuvant
chemotherapy-treated cohort (NAC, n=55 patients) of lung squamous cell carcinomas (LSCC). For each patient,
the slide showing the least pathologic regression was selected for subsequent computational analysis and his-
tological features were quantified: percentage of vital tumor cells (cTu.Percentage), total surface covered by vital
tumor cells (cTu.Area), area of the largest vital tumor fragment (cTu.Size.max), and total number of vital tumor
fragments (cTu.Fragments). A chemo-naïve LSCC cohort (CN, n= 104) was used for reference. For 23 of the 55
patients [18F]-Fluorodeoxyglucose (FDG) PET/CT measurements of maximum standard uptake value (SUVmax),
background subtracted lesion activity (BSL) and background subtracted volume (BSV) were correlated with
pathologic regression. Survival analysis was carried out using Cox regression and receiver operating char-
acteristic (ROC) curve analysis using a 3-years cutoff.
Results: All computational regression parameters significantly correlated with relative changes of BSV FDG PET/
CT values after neoadjuvant chemotherapy. ROC curve analysis of histological parameters of NAC patients
showed that cTu.Percentage was the most accurate prognosticator of overall survival (ROC curve AUC=0.77, p-
value= 0.001, Cox regression HR=3.6, p=0.001, variable cutoff< =30 %).
Conclusions: This study demonstrates the prognostic relevance of computer-derived histopathologic scores.
Additionally, the analysis carried out on slides displaying the least pathologic regression correlated with overall
pathologic response and PET/CT values. This might improve the objective histopathologic assessment of tumor
response in neoadjuvant setting.
1. Introduction
In a neoadjuvant setting, the administration of chemotherapy before
surgery may result in significant reduction of the tumor burden, thus
enabling radical resection in otherwise not operable patients. This
treatment strategy has been shown to improve both overall (OS) [1]
and recurrence-free survival (RFS) in resectable non-small cell lung
carcinoma (NSCLC) [2]. Neoadjuvant chemotherapy induces distinctive
morphological changes of both tumor and stromal compartments of
solid carcinomas. This often results in significant reduction of tumor
burden, which is accompanied by an increase of fibrotic stroma and
necrosis as well as an increased infiltration by foamy cell macrophages
[3].
Although there is no WHO-accepted consensus for regression
scoring of NSCLC [4], the extent of residual vital tumor epithelia to-
gether with the amount of fibrosis are important prognostic parameters
[5]. Several regression scoring systems have been proposed for this
tumor based on the percentage of remaining tumor cells [6–8] or the
residual tumor area [9]. However, most scoring methods rely on a semi-
quantitative and visual pathologic evaluation of the residual tumor
burden on H&E stained whole sections. Therefore, accurate quantifi-
cation of morphologic parameters including amount and size of residual
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tumor tissue could be useful for improving and standardizing current
NSCLC regression schemes [10]. Junker et al. proposed a regression
scheme in 3 grades starting from a grade 1 defined as no or only
spontaneous regression, a grade 2 as incomplete regression (2a
with> 10 %, 2b with≤10 % vital tumor cells) and grade 3 as complete
regression without any detectable vital tumor cells [6,7]. Following
these results, it has been shown that NSCLC with less than 10 % of
residual vital tumor cells [8,11], a histopathological complete remis-
sion (CR) [12,13] or a total area of residual tumor (ART) ≤400 mm2
[9] were favorable prognostic parameters. Thus, the automatic quan-
tification of morphologic parameters could be a good indicator of the
effectiveness of therapy in NSCLC [10].
The field of tissue diagnostics is witnessing substantial changes with
the recent approval of Whole Slide Imaging (WSI) for primary diagnosis
[14] and the rapid development of not only information management
systems but also digital image analysis tools encompassing im-
munohistochemical staining scoring, detection of regions of interest
displaying abnormalities and other prognostic algorithms. Hence,
computational pathology has the potential to integrate routine pa-
thology workflow and reduce pathologist’s workload by performing
time-consuming tasks [15,16].
We have previously developed an image analysis approach to
quantify tumor fragmentation [17] in lung squamous cell carcinoma
(LSCC), the second most common histological subtype of NSCLC [18].
This structural feature was associated with increased tumor invasion
and poor prognosis. Herein, we have extended our approach to evaluate
the potential clinical relevance of four computerized morphologic
parameters related to the residual tumor burden in a cohort of 55
neoadjuvant treated (NAC) LSCC. We investigated the prognostic value
of computational tumor regression scoring in comparison to conven-
tional histopathologic regression scoring and further evaluated their
correlation with [18F]- Fluorodeoxyglucose (FDG)PET/CT-based tumor
metabolic activity parameters.
2. Materials and methods
2.1. Patient cohorts
In this retrospective study, patients with diagnosed primary LSCC at
the University Hospital Zurich were selected. Patients with synchronic
or metachronic second primary tumor, with overall survival (OS)< 1
month post-surgery and/or with incomplete clinical data were ex-
cluded. Squamous cell differentiation according to WHO criteria was
assessed on hematoxylin-eosin (H&E) stains and verified by alcian blue-
periodic acid schiff (AB-PAS) histochemistry as well as TTF1, p40, CK7
and synaptophysin immunohistochemistry (IHC) for poorly differ-
entiated LSCC. The neoadjuvant chemotherapy group (NAC cohort)
consisted of 55 patients diagnosed with LSCC with a median follow-up
time of 51 months (range: 2–141). In total 19 patients received gem-
citabine-platinum chemotherapy, 26 taxane-platinum and 10 other
combinations. Chemotherapy cycles ranged from two to five (2 cycles:
n= 3, 3 cycles n=43, 4 cycles: n= 7, 5 cycles: n= 2.
Histopathological regression after neoadjuvant chemotherapy was
evaluated by microscopy by two observers simultaneously on H&E
tissue sections. The tumor regression grade (TRG) was evaluated on all
available tissue blocks and referred to the amount of non-vital tumor
tissue induced by the chemotherapy - characterized by the presence of
extensive necrosis and fibrosis, foamy cells reactions and cholesterol
crystals - in relation to the remaining vital tumor cells. TRG was eval-
uated as follows : complete pathologic response (CPR, 0% of remaining
tumor cells), major pathologic response (MPR,< 10 % remaining
tumor cells) and minor pathologic response (IPR > 10 % remaining
tumor cells) similar to [5]. The chemo-naïve cohort (CN) consisted of
104 patients with a median follow-up time of 52 months (range:
2–137). The ethical commission of the Canton of Zurich approved the
study under reference number KEK ZH-Nr. 29-2009/14.
2.2. Histopathological samples preparation
For each neoadjuvant treated case, one tissue block with the highest
amount of residual tumor tissue (i.e. the least pathologic regression)
was selected for pan-cytokeratin IHC. For the chemo-naïve cases, two
representative tumor blocks were selected to perform a comparative
analysis. Tissue sections of 2 μm thickness were prepared for the se-
lected tumor blocks and IHC was performed using mouse monoclonal
anti-human cytokeratin AE1/AE3 (M3515, DAKO, dilution 1:50) on an
automated platform (Ventana Medical Systems, Tucson, AZ, USA). The
following detection was finalized with a secondary antibody and the
OptiView DAB kit (Ventana Medical Systems). IHC stained sections
were scanned using a high-resolution whole slide scanner (Nanozoomer
Digital Pathology, Hamamatsu, Japan) using a 40x objective and
downscaled to a spatial resolution of 0.23 μm/pixel. Tumor tissue was
manually annotated by a surgical pathologist (A.S.) in order to exclude
surrounding non-tumor lung tissue from the analysis.
2.3. Image processing and regression scoring
For the CN cohort, a color threshold was used to segment malignant
tumor tissue (brown positive signal) from its surrounding desmoplastic
stroma (blue-grey counterstain) using Fiji [19], as described [17].
Morphologic parameters of the segmented tumor tissue were retrieved
for each tumor specimen and computed as following: 1. percentage of
vital tumor cells (cTu.Percentage = tumor cells area/[tumor cells
area+ stroma area]*100), 2. total surface covered by vital tumor cells
(cTu.Area), 3. size of the largest vital tumor fragment (cTu.Size.max), 4.
total number of vital tumor fragments (cTu.Fragments), defined as
disconnected carcinoma fragment larger than 800 μm2, separated by
stroma. As chemo-treated cases often show extensive necrosis or un-
specific staining, tissue segmentation of vital tumor epithelia versus
necrosis and/or unspecific stromal staining was performed by a train-
able algorithm using the software inForm Tissue Finder™ (PerkinElmer,
Waltham, MA, USA).
2.4. FDG PET/CT acquisition and analysis
Patients from the NAC cohort with available FDG PET/CT before
and after neoadjuvant treatment (before tumor resection) were ana-
lyzed. FDG PET/CT selection criteria were: fasting for at least 4 h, no
elevated blood glucose, adequate FDG injection (difference< 100MBq
between both FDG injections), FDG uptake time within 45−60min and
acceptable image quality. For a total of 23 patients, pre and post-
neoadjuvant chemotherapy images were available. The detailed pro-
tocol is explained in our previous study [20]. Metabolic tumor activity
was measured following the instructions as described [21] and was
performed without knowledge of regression scores. The maximum
Standard Uptake Value (SUVmax), background subtracted lesion activity
(BSL) and background subtracted volume (BSV) were considered in this
analysis. In brief, a volume of interest was placed around the primary
tumor, including the entire tumor activity without regions of physio-
logically increased activity (e.g. FDG-uptake of the heart). Within the
selected VOI SUVmax, BSL and BSVusing a background adapted
threshold for each lesion were measured [22]. The relative change in
FDG-PET metrics between post- and pre-neoadjuvant chemotherapy
was calculated (dSUVmax, dBSL and dBSV).
2.5. Data interpretation and statistical analysis
All statistical analyses were performed on SPSS version 25 software
(SPSS Inc., Chicago, USA), R version 3.5.0 and R-studio version 1.1.383.
Overall survival (OS) and relapse-free survival (RFS) were evaluated
from the date of surgery to the date of death or documented relapse, as
described [23]. Only patients with no evidence of remaining tumor
after surgical resection of the primary tumor (R0) were included in RFS
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calculations. Quantitative morphologic differences between neoadju-
vant chemo-treated (NAC) and chemo-naïve (CN) groups were ad-
dressed using the Wilcoxon signed-rank test. Correlations between the
FDG PET/CT metrics (SUVmax, BSL and BSV) and the morphologic
parameters (cTu.Percentage, cTu.Area, cTu.Size.max, cTu.Fragments)
were calculated using the non-parametric Spearman’s rank correlation
test. A receiver operator characteristic (ROC) curve was generated for
each morphologic parameter using a cutoff of 3-year OS and RFS to
separate short and long-term survivors. The area under the ROC curve
(AUROC) was computed for each parameter. Patients with clinical
follow-up shorter than 3 years were omitted in the ROC analysis. The
optimal cutoff point was determined for each parameter with the point
that minimizes the distance to the top-left corner in the ROC plane as
described [24]. Kaplan-Meier curve p-values were calculated using the
log-rank test. Hazard ratios were retrieved by univariate Cox regression.
Ordinal categorical variables were coded using Reverse Helmert coding
(each level of categorical variable is compared to the mean of the
previous level). P-values< 0.05 were considered significant.
3. Results
3.1. Neoadjuvant treatment induces significant morphologic changes in
LSCC tissue
Morphologic changes after neoadjuvant treatment were addressed
by comparing the NAC cohort with the untreated CN group. In total
four computerized morphologic parameters representing the percen-
tage of tumor cells within the tumor area (cTu.Percentage), the total
tumor cells surface (cTu.Area), the largest fragment (cTu.Size.max) and
the total number of tumor fragments (cTu.Fragments) were quantified
by image-based morphometric analysis for all LSCC cases (Fig. 1A–C).
The distribution of these morphometric parameters was significantly
different between the two cohorts and all four parameters were con-
siderably reduced in the NAC compared to CN group (all p-values<
0.001) (Fig. S1, A–H). Histological examples of NAC LSCCs showing
different regression patterns are shown in Fig. 1(D–F).
Within the NAC group, morphologic alterations were compared
between gemcitabine-platinum (n=19) and taxane-platinum (n= 26)
regimens excluding other treatment combinations. Results showed that
cTu.Area and cTu.Size.max values were lower for the taxane-platinum
treated group, using the non-parametric Mann-Whitney U test
(p= 0.040 and p=0.009, respectively) (Figure S2).
3.2. Computerized histological regression scoring improves LSCC prognostic
stratification
The distribution of clinic-pathologic parameters for the NAC and CN
cohorts is summarized in Table 1. The CN cohort showed similar clin-
ical parameters distributions. In the NAC cohort particularly, age, ypN,
ypM and stage were prognostic parameters whereas no survival dif-
ference was observed between different chemotherapy regimens
(p=0.239).
To better compare the prognostic relevance of clinical and compu-
tational parameters, ROC analysis was performed with patients strati-
fied into short-term and long-term survival, using a threshold of 3-year
OS. In the NAC cohort, 22 and 33 patients were respectively grouped
like this. In the CN cohort, 37 and 67 patients were split into short and
long-term OS. The results for the NAC cohort showed that the para-
meters cTu.Percentage, cTu.Area, and cTu.Size.max were able to sig-
nificantly stratify patients in two risk groups, using a 3-year OS cutoff,
whereas cTu.Fragments was not prognostic (Fig. 2, A). The parameters
cTu.Area and cTu.Size.max were consistently prognostic using a 3-year
RFS cutoff point (Figure S3). In contrast, for CN patients, cTu.Percen-
tage, cTu.Area, and cTu.Size.max were not significant parameters
whereas cTu.Fragments was the best discriminative morphologic
parameter using 3-year OS and RFS cutoffs (Figure S4).
Following these results, further clinical analysis was conducted on
the NAC cohort focusing on clinic-pathologic parameters. ROC analysis
showed that stage, ypN and TRG were able to stratify patients in two
risk groups, whereas ypT was not significant (Figure S5). Stage and ypN
showed the highest area under the ROC (AUROC) and were comparable
with the computational parameter cTu.Percentage. Similar results were
found using a 3-year RFS cutoff (Figure S3, B). Additionally, univariate
cox regression was performed for all computational parameters as well
as most relevant clinico-pathologic parameters, dichotomized at their
optimal cutoff point (Table 2). High cTu.Percentage and cTu.Size.max
values were significantly associated with decreased OS, whereas
cTu.Area, cTu.Fragments and TRG scores were not significantly prog-
nostic (p > 0.05). Kaplan Meier survival curves are shown in
Fig. 2(B–G).
3.3. Computational histological regression correlates with relative FDG
PET/CT metabolic changes before and after neoadjuvant chemotherapy
The correlation of histopathological regression with tumor meta-
bolic activity was addressed using pre- and post-NAC FDG PET/CT
scans. Relative changes between pre- and post-chemo were also con-
sidered in the analysis (delta values). Histopathological regression was
evaluated using all four computational parameters (cTu.Percentage,
cTu.Area, cTu.Size.max, and cTu.Fragments) in addition to the con-
ventional TRG scores.
The comparison of pre-NAC, post-NAC and the corresponding re-
lative changes (delta-NAC) FDG PET/CT parameters showed, that post-
NAC FDG PET/CT volumetric values (BSL and BSV) positively corre-
lated with all computational parameters whereas pre-NAC FDG PET/CT
values did not show any significant correlation with any tumor re-
gression parameter (Fig. 3). Among all FDG PET/CT values, the volume-
based metric dBSV correlated best with all regression parameters on
both post-NAC and delta-NAC settings. Both post-NAC and delta-NAC
SUVmax significantly correlated with c.Tu.Percentage and TRG only.
Among the computed regression parameters, cTu.Percentage was the
only one consistently correlating with all FDG PET/CT parameters post
NAC.
4. Discussion
In this study we proposed an approach to quantify tumor regression
in lung squamous cell carcinoma after neoadjuvant chemotherapy by
computational pathology. Four computational histo-morphologic
parameters related to the residual tumor burden were quantified using
pan-cytokeratin immunohistochemistry and compared to the patho-
logic response using a three-tiered tumor regression scoring system
assessed by the pathologist on H&E stained whole section microscopy.
Correlations with FDG PET/CT values and clinical outcome were as-
sessed in order to address the potential clinical relevance of quantita-
tive tumor regression readouts for routine response assessment after
neoadjuvant therapy.
We focused our study on the morphologic changes induced by NAC
in a cohort of lung squamous cell carcinoma (LSCC). Unlike adeno-
carcinoma which grows in five distinct morphologic patterns [25],
LSCC is histologically characterized by the presence of solid tumor
epithelia sheets of varying size and cohesiveness displaying various
degrees of keratinization [26]. Our morphometric analysis showed that
cTu.Percentage, cTu.Area, cTu.Size.max and cTu.Fragments were all
significantly decreased in neoadjuvant chemotherapy treated patients
when compared to a chemo-naïve cohort. Moreover, survival analysis
showed that high residual cTu.Percentage, cTu.Area and cTu.Size.max
values after neoadjuvant chemotherapy were markers of poor prog-
nosis. In contrast, these parameters were not prognostic in the chemo-
naïve setting, whereas cTu.Fragments, a parameter reflecting tumor
invasiveness, was prognostic only in this group of patients. This also
suggests that computational histo-morphologic parameters may allow
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Fig. 1. Computerized morphometric analysis. A) Overview of a lung squamous cell carcinoma stained by pan-cytokeratin IHC. Scale bar: 10mm. Left:
Corresponding schematic of the sampling strategy. The top section represents the slide with the least regression (i.e. highest amount of residual tumor tissue) selected
for morphometric analysis. (Legend: brown= vital tumor content, grey= regressed tumor area without vital tumor cells. Top-right: magnified area of interest, scale
bar: 1mm. B) Corresponding tissue detection (overlay) after trainable tissue region segmentation. Legend: T= tumor tissue (red); S= stroma (green); U= unspecific
staining (yellow), accounting for stroma. C) Analysis of tumor fragments i.e. connected tumor regions and corresponding masks colored by size in μm2. D-F)
Histological example of NAC treated LSCCs showing different degrees of tumor regression (D) IPR with no signs of regression, (E) IPR with minor signs of regression,
(F) MPR with<10 % vital tumor cells. Scale bar= 200 μm.
Table 1
Univariate Cox regression analysis and summary of clinico-pathologic parameters.
Clinicopathologic parameters Neoadjuvant chemo-treated (NAC) n=55 Chemo-naïve (CN) n= 104
N % HR CI (95 %) p N % HR CI (95 %) p
Age range: 40−76 years 0.049 Age range: 40−87 years 0.207
≤median (61) 28 (51 %) 1.0 – – ≤median (65) 55 (53 %) 1.0 – –
>median 27 (49 %) 1.4 (1.0−2.0) 0.049 > 65 49 (47 %) 1.3 (0.8−2.2) 0.207
Sex 0.897 Sex 0.190
female 12 (22 %) 1.0 – – female 21 (20 %) 1.0 – –
male 43 (78 %) 1.1 (0.45−2.47) 0.897 male 83 (80 %) 0.7 (0.4−1.2) 0.190
ypT 0.658 pT <0.001
0 5 (9%) 1.0 – –
1 19 (34 %) 3.4 (0.4−26.7) 0.241 1 24 (23 %) 1.0 – –
2 13 (24 %) 1.5 (0.4−5.3) 0.498 2 34 (33 %) 1.203 (0.6−2.4) 0.604
3 7 (13 %) 1.8 (0.5−6.9) 0.412 3 34 (33 %) 1.827 (1.1−3.1) 0.027
4 11 (20 %) 1.9 (0.7−5.0) 0.199 4 12 (12 %) 3.787 (2.0−7.3) <0.001
ypN 0.010 pN 0.075
0 26 (47 %) 1.0 – 0 49 (47 %) 1.0 – –
1 20 (37 %) 0.9 (0.4−2.1) 0.795 1 34 (33 %) 1.808 (1.1−3.1) 0.032
2−3 9 (16 %) 3.7 (1.6−8.7) 0.002 2−3 21 (20 %) 1.24 (0.7−2.2) 0.462
ypM 0.014 pM <0.001
0 54 (98 %) 1.0 – – 0 100 (96 %) 1.0 – –
1a-c 1 (2%) 17.3 (1.8−166.55) 0.014 1a-c 4 (4%) 27.0 (7.6−95-7) <0.001
Stage 0.005 Stage <0.001
0 5 (9 %) 1.0 – –
I 13 (23 %) 2.3 (0.3−18.6) 0.450 I 26 (25 %) 1.0 – –
II 14 (26 %) 1.4 (0.4−5.0) 0.629 II 38 (37 %) 1.4 (0.7−2.8) 0.326
III 22 (40 %) 4.1 (1.6−10.6) 0.004 III 36 (35 %) 2.2 (1.3−3.7) 0.002
IV 1 (2%) 27.5 (2.7−280.3) 0.005 IV 4 (4%) 30.1 (8.4−107.4) <0.001
Legend: NAC=neoadjuvant chemotherapy; CN= chemo-naive; HR=hazard ratio; CI= 95 % confidence interval; p(T/N/M)=pathologic evaluation (y) after
neoadjuvant chemotherapy.
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for differential tumor grading for patients having received che-
motherapy prior to surgical resection. In this study, although compu-
tational morphologic parameters were highly correlated with each
other, ROC analysis showed that cTu.Percentage was the most relevant
qualifier for the stratification of patients into high and low risks cate-
gories, using a 3-year OS cutoff. When compared to clinical parameters,
cTu.Percentage showed similar performances than tumor stage and
lymph node involvement as well as better performances than TRG
scores described in [6,7].
FDG PET/CT is a valuable imaging modality to predict histological
response after neoadjuvant therapy [27]. In our study, PET/CT-mor-
phometry correlation analysis was performed using the SUVmax in ad-
dition to two volume-based PET values accounting for the lesion ac-
tivity (BSL) and the metabolic tumor volume (BSV) as metrics of tumor
metabolic activity. Our analysis showed that computed regression
parameters correlated best with BSV for both post-NAC and delta-NAC
FDG PET/CT, whereas SUVmax was only associated with the percentage
of residual tumor cells and TRG scores. This could be potentially re-
levant when reporting PET/CT values, since the metabolically active
tumor volume could better reflect histological features compared to
SUVmax. Not surprisingly, our analysis showed that, overall, pre-NAC
FDG PET/CT values did not correlate with the measured histological
parameters. This is in line with previous studies, showing that the
change of standardized uptake values correlate with histopathologic
responses in NSCLC [28–33] whereas pre-chemo PET/CT is likely to be
insufficient to predict pathologic response in LSCC [30].
Our study has nonetheless limitations. The morphometric analysis
was performed using the tissue block showing the least pathologic re-
gression and pan-cytokeratin IHC, whereas following the most recent
recommendations, pathologic response to therapy should include all H
&E slides of tumor [5]. For this reason, our cTu.Percentage scores are
virtually higher and cannot be directly compared with previously
published pathologic scores. However, our survival analysis showed
that regression scores done on the histological cut section displaying
the least regression pattern, was significantly prognostic and showed
better prediction performances than TRG scores. Follow-up studies
could assess whether the least histological regression would be a better
prognosticator than evaluating tumor regression over the whole tumor
area for LSCC. Additionally, our study focused solely on squamous cell
carcinoma of the lung, which is a subtype of NSCLC. Adenocarcinomas
are grouped into five morphologic subtypes: lepidic, acinar, papillary,
micropapillary and solid [25]. These morphologic patterns significantly
affect FDG uptake [34] and it has been shown that squamous cell car-
cinomas have higher SUV uptake than adenocarcinomas [35–39].
Therefore, in order to study a homogeneous population by morpho-
metrics and PET analyses, only LSCC were selected in our study. Finally,
we presented here a retrospectively study. To determine whether
computerized regression scoring could serve as surrogate histopatho-
logical response assessment with clinical benefit, larger validation
studies would be required.
5. Conclusions
The field of pathology is witnessing substantial transformations,
with the growing acceptance of whole slide imaging for full sign-out of
Fig. 2. ROC curves and survival analysis of morphologic parameters for neoadjuvant-treated patients. A) Receiver operator characteristic (ROC) curves for the
status 3-year overall survival using computational morphologic parameters (C-Parameters) for all NAC patients. B-G) Kaplan Meier survival curves for all C-
Parameters as well as histopathological TRG scores (CPR= complete pathologic response, MPR=major pathologic response, IPR=minor pathologic response).
AUC= area under the curve; CI= confidence interval; cTu.Percentage= percentage of tumor cells within the whole tumor tissue; cTu.Area= vital tumor cells area
[mm]; cTu.Size.max= area of the largest fragment [mm]; cTu.Fragments= number of tumor fragments separated by stroma; time=months.
Table 2
Cox regression analysis of morphologic parameters.
Variables Univariate
HR CI (95 %) p-value
cTu.Percentage < 31 3.6 (1.7–7.5) 0.001
cTu.Area < 36 1.9 (0.9–3.9) 0.077
cTu.Size.max < 18 3.0 (1.5–6.4) 0.003
cTu.Fragments < 261 0.6 (0.3–1.3) 0.230
TRG (CPR+MPR vs IPR) 1.9 (0.9–4.0) 0.094
multivariate
HR CI (95 %) p-value
Stage 0-II vs III-IV 2.6 (1.1–6.1) 0.028
cTu.Percentage < 31 2.6 (1.2–5.8) 0.016
Top: cox univariate analysis using the computational morphologic parameters
cTu.Percentage, cTu.Area, cTu.Size.max, cTu.Fragments dichotomized at the
best cutoff point. TRG=pathological tumor regression grade, dichotomized.
Bottom: multivariate cox regression using the dichotomized Stage (0, I, II vs III-
IV) and cTu.Percentage (cutoff=31). Legend: HR=hazard ratio; CI= 95 %
confidence interval, CPR= complete pathologic response, MPR=major pa-
thologic response, IPR=minor pathologic response.
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diagnostic surgical pathology [40] and the accelerated development of
computational pathology applications. Artificial intelligence algorithms
capable of detecting lymph node metastases on histological images
from breast cancer patients [41,42], or able to predict histopathological
parameters as well as patient outcome using histological sections
[43–48] are few examples of prospective opportunities of computa-
tional pathology to assist pathologists in their daily routine. Reprodu-
cibility studies are currently needed to better assess pathologic response
in the neoadjuvant setting and computational approaches could play
major role in harmonizing pathologic response readouts [5]. In our
study, we have proposed a digital pathology approach for accurate
histopathologic assessment of tumor regression after neoadjuvant che-
motherapy and curative surgery. This approach is not restricted to LSCC
nor to a specific type of treatment. It has the potential to be applied to
larger clinical studies who would benefit from reproducible and quan-
titative histological readouts of treatment response. The histopatholo-
gist would thereby obtain an additional independent computerized re-
gression score.
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